open access

Vol 79, No 10 (2008)
ARTICLES
Get Citation

Statement of the Expert Group of Polish Gynecologic Society on the cervical adenocarcinoma prophylaxis

Ginekol Pol 2008;79(10).

open access

Vol 79, No 10 (2008)
ARTICLES

Abstract

The group of experts representing the Polish Gynecologic Society has issued this Statement based on the review of available literature on the epidemiology of cervical adenocarcinoma and the most effective methods of its prophylaxis. Although the incidence of squamous cell cervical carcinomas has declined in the last 30 years, that of cervical adenocarcinoma has significantly increased in recent years, especially among young women. This rise in incidence obviously results from the fact that routinely used screening methods such as Pap test fail to detect a substantial proportion of the glandular precursor lesions. HPV infection constitutes the key risk factor for cervical adenocarcinoma. Three most prevalent HPV types (16,18 and 45) account for 92% of cases of cervical adenocarcinoma. From the point of view of the adenocarcinoma prophylaxis, it is important that a significant cross-protection against persistent infection with HPV type 45 has been shown for the bivalent HPV vaccine. It has been estimated that the protective efficacy of the HPV vaccination with respect to the cervical adenocarcinoma exceeds that regarding squamous tumors by nearly 20%. Large-scale implementation of HPV vaccination with the vaccines that target the most predominant virus types associated with cervical adenocarcinoma seems to be the most effective way to reduce both the incidence and mortality rates of this cancer.

Abstract

The group of experts representing the Polish Gynecologic Society has issued this Statement based on the review of available literature on the epidemiology of cervical adenocarcinoma and the most effective methods of its prophylaxis. Although the incidence of squamous cell cervical carcinomas has declined in the last 30 years, that of cervical adenocarcinoma has significantly increased in recent years, especially among young women. This rise in incidence obviously results from the fact that routinely used screening methods such as Pap test fail to detect a substantial proportion of the glandular precursor lesions. HPV infection constitutes the key risk factor for cervical adenocarcinoma. Three most prevalent HPV types (16,18 and 45) account for 92% of cases of cervical adenocarcinoma. From the point of view of the adenocarcinoma prophylaxis, it is important that a significant cross-protection against persistent infection with HPV type 45 has been shown for the bivalent HPV vaccine. It has been estimated that the protective efficacy of the HPV vaccination with respect to the cervical adenocarcinoma exceeds that regarding squamous tumors by nearly 20%. Large-scale implementation of HPV vaccination with the vaccines that target the most predominant virus types associated with cervical adenocarcinoma seems to be the most effective way to reduce both the incidence and mortality rates of this cancer.
Get Citation

Keywords

profilaktyka, epidemiologia, rak szyjki macicy

About this article
Title

Statement of the Expert Group of Polish Gynecologic Society on the cervical adenocarcinoma prophylaxis

Journal

Ginekologia Polska

Issue

Vol 79, No 10 (2008)

Bibliographic record

Ginekol Pol 2008;79(10).

Keywords

profilaktyka
epidemiologia
rak szyjki macicy

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl